# Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

> **NCT00005951** · PHASE1 · COMPLETED · sponsor: **Duke University**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00005951
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** — (—)
- **Last updated:** 2014-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005951, "Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00005951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*